SetPFPGroupVar.htm
   
SetPProProdListVar.htm

New User? Register Now

Returning User? Sign In

Benefits of registering


login.htm

Visit other Pfizer sites
Search Medical Responses
View an extensive list of Pfizer sites
ppn-vr-sso-links.htm

Share Your Feedback
Product Centers | Sutent(R) (sunitinib malate)
 

Indication
SUTENT is indicated for the treatment of:

  • Advanced renal cell carcinoma (RCC)
  • Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate

Featured Content

Updated Results for SUTENT in mRCC

Now available: Journal of Clinical Oncology reprint on overall survival (OS) with sunitinib versus interferon alfa (IFNα) as first-line treatment of metastatic renal cell carcinoma (mRCC). Access the reprint now.


SUTENT Overall Survival in mRCC

Median OS has been reached in the phase 3 study comparing sunitinib with IFNα in the first-line treatment of mRCC.1 See the OS data now.


SUTENT MOA

Watch Dr Christopher Ryan discuss how SUTENT inhibits tumor progression. View the video now.

 

SUTENT Patient Call Center Now Open

Patients can call 1-877-5-SUTENT Monday through Friday from 8 AM To 7 PM CT to speak to trained oncology nurses. The nurses do not provide medical advice, but reinforce general information about SUTENT, including:

  • Potential side effects
  • Treatment information
  • RCC and GIST information


View the patient call center brochure.


Reference:
1. Data on file. Pfizer Inc, New York, NY.

Important Safety Information for SUTENT
Sutent (sunitinib malate)

Back to Top

Important Safety Information for Aromasin AROMASIN® (exemestane tablets)

Back to Top

Important Safety Information for Camptosar CAMPTOSAR® (irinotecan hydrochloride injection)

Back to Top

Important Safety Information for Ellence Ellence® (epirubicin hydrochloride injection)

Back to Top

SUTENT Safety Information